AUPH Q3 2023 Earnings — Aurinia Pharmaceuticals Inc. Revenue & Financial Results | Market Cap Arena

AUPHAurinia Pharmaceuticals Inc.

$2B

Q3 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$55M-2.3% YoY

Gross Profit

$48M87.6% margin

Operating Income

-$16M-29.8% margin

Net Income

-$13M-24.7% margin

EPS (Diluted)

$-0.09

QoQ Revenue Growth

+31.4%

Cash Flow

Operating Cash Flow

-$13M

Free Cash Flow

-$13M

Stock-Based Comp.

$12M

Balance Sheet

Total Assets

$555M

Total Liabilities

$163M

Stockholders' Equity

$392M

Cash & Equivalents

$46M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$55M	$56M	-2.3%
Gross Profit	$48M	$53M	-10.5%
Operating Income	-$16M	-$9M	-71.2%
Net Income	-$13M	-$9M	-49.6%

Revenue Segments

Product

$41M75%

License, Royalty and Collaboration Revenue

$14M25%